AKR1B10 and COVID-19: Figure 4). Therefore, during COVID-19, it is possible that a high blood concentration of AKR1B10 is a consequence of an increased expression of AKR1B10 in the lung, and that the AKR1B10 transport through the blood stream could favour the production of pro-inflammatory cytokines in various organs other than the lung, which could participate to the multi-systemic effects associated with COVID-19 related ARDS. The study of Daamen et al. [28] which shows no difference in the mRNA transcription of AKR1B10 in the peripheral blood monocytes of COVID-19 patients also supports this hypothesis.